HomeAI · summaries
Storia in 3 fonti
RallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
RallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
- ·
endpoints.news
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio.
